Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Xingnao Kaiqiao Acupuncture Method Combined with Temporal Three-Needle in the Treatment of Acute Ischemic Stroke: A Randomized Controlled Trial

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          The objective of this study was to investigate the difference between the clinical effectiveness of two acupuncture methods in the treatment of acute ischemic stroke (AIS) and provide more evidence-based medical evidence of acupuncture's effectiveness in stroke rehabilitation.

          Methods

          We conducted an outcome assessor-and data analyst-blinded, randomized, and controlled trial. Seventy-two participants were randomly allocated to the observation group and control group with a 1 : 1 allocation ratio by the generating of a random number table.The observation group received the “Xingnao kaiqiao” acupuncture method combined with “Temporal three needles,” and the control group received conventional acupuncture “Scalp acupuncture” combined with the traditional “body acupuncture” method. The acupuncture treatment was performed once per day for one week by trained acupuncturists. Both groups underwent secondary prevention of cerebral infarction and received a 3-months' followup. After a 1-week acupuncture intervention, the changes of NIHSS (National Institutes of Health Stroke Scale) scores, Percent Change and Absolute Change of NIHSS scores, MBI (Modified Barthel Index), and the rate of MBI ≥ 80 in two groups were observed. After 3 months' followup, the mRS (Modified Ranking Scale) and the clinical efficacy of the two groups were compared.

          Results

          The apparent efficiency rate of the observation group was 63.9%, higher than 19.4% of the control group, and the difference was significant ( P < 0.05). After treatment, NIHSS scores, Percent Change, and Absolute Change of NIHSS scores in the observation group had a significant reduction than the control group (all P < 0.05). MBI in the observation group increased significantly more than in the control group ( P < 0.05), but the rate of MBI ≥ 80 in the two groups was not significantly different ( P > 0.05). After 3 months' of followup, the mRS score frequencies of the observation group were not statistically different from the control group ( P > 0.05). The rate of mRS scores of 0–1 in the observation and control group were 55.6% and 38.9%, and there was no significant difference either ( P > 0.05).

          Conclusion

          Compared with “Scalp acupuncture” combined with “body acupuncture,” “Xingnao kaiqiao” acupuncture method combined with “Temporal three-needle” had superiority in the improvement of neurological deficit, potential functional disability, and score of basic activities of daily living. As to the independent rate to basic activities of daily living and good prognosis of 3 months, there were no statistical differences.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: not found
          • Article: not found

          Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            NXY-059 for the treatment of acute ischemic stroke.

            The free-radical-trapping agent NXY-059 showed promise as a neuroprotectant in the Stroke-Acute Ischemic NXY Treatment I (SAINT I) trial, reducing disability when given to patients who had acute ischemic stroke. We sought confirmation of efficacy in a second, larger trial. We enrolled 3306 patients with acute ischemic stroke in a randomized, double-blind trial to receive a 72-hour infusion of intravenous NXY-059 or placebo within 6 hours after the onset of stroke symptoms. Our primary end point was the distribution of disability scores on the modified Rankin scale at 90 days. We examined scores on neurologic and activities-of-daily-living scales as secondary end points. We also tested the hypothesis that NXY-059 would reduce alteplase-related intracranial hemorrhages. The efficacy analysis was based on 3195 patients. Prognostic factors were well balanced between the treatment groups. Mortality was equal in the two groups, and adverse-event rates were similar. The distribution of scores on the modified Rankin scale did not differ between the group treated with NXY-059 (1588 patients) and the placebo group (1607 patients; P=0.33 by the Cochran-Mantel-Haenszel test; odds ratio for limiting disability, 0.94; 95% confidence interval [CI], 0.83 to 1.06). Analysis of categorized scores on the modified Rankin scale confirmed the lack of benefit: the odds ratio for trichotomization into modified Rankin scale scores of 0 to 1 versus 2 to 3 versus 4 to 6 was 0.92 (95% CI, 0.80 to 1.06). There was no evidence of efficacy for any of the secondary end points. Among patients treated with alteplase, there was no difference between the NXY-059 group and the placebo group in the frequency of symptomatic or asymptomatic hemorrhage. NXY-059 is ineffective for the treatment of acute ischemic stroke within 6 hours after the onset of symptoms. (ClinicalTrials.gov number, NCT00061022 [ClinicalTrials.gov].) Copyright 2007 Massachusetts Medical Society.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Update on Treatment of Acute Ischemic Stroke

                Bookmark

                Author and article information

                Contributors
                Journal
                Comput Intell Neurosci
                Comput Intell Neurosci
                cin
                Computational Intelligence and Neuroscience
                Hindawi
                1687-5265
                1687-5273
                2022
                29 June 2022
                : 2022
                : 8145374
                Affiliations
                Meizhou People's Hospital, Meizhou 514031, Guangdong, China
                Author notes

                Academic Editor: Dong Chen

                Author information
                https://orcid.org/0000-0002-7483-1785
                Article
                10.1155/2022/8145374
                9259275
                35814561
                303946d5-dd36-4534-be41-624b5d41c815
                Copyright © 2022 Zhongtao Song et al.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 11 May 2022
                : 1 June 2022
                : 6 June 2022
                Funding
                Funded by: Meizhou Medical and Health Research Project
                Award ID: 2020B67
                Funded by: Inheritance and Development of TCM in Guangdong
                Award ID: 20202206
                Categories
                Research Article

                Neurosciences
                Neurosciences

                Comments

                Comment on this article